forex signal system trading: NASDAQ: Biotech Stock Alert

You're receiving this email because you are subscribed to Options Profits Daily,
if you no longer wish to receive these emails you can unsubscribe here.

New Drug Candidate To Target Most Aggressive Type Of Brain Cancer Received Positive FDA Pre-IND Guidance

Dear Reader,

The NASDAQ stock exchange is abundant with emerging growth biotech stocks, but there is one company that is on our radar that is targeting the most aggressive type of brain cancer that was developed at the largest cancer treatment and research institute in the world.

They recently IPO'd at $4 per share and they are preparing to begin their Phase II clinical trials.

We've put together a detailed report on why we believe it offers investors a unique opportunity in the biotech space.

Click here for more details.

RISK DISCLAIMER: Before deciding to participate in any investment, you should carefully consider your investment objectives, level of experience and risk tolerance. Most importantly, do not invest money you cannot afford to lose. Trade Stocks is not a registered broker-dealer. Trade Stocks does not give investment advice, endorsement, analysis or recommendations with respect to any securities. Trade Stocks has not taken any steps to verify the adequacy, accuracy or completeness of any information. Neither Trade Stocks nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Trade Stocks does not make investment recommendations and no communication, through this website or in any other medium should be construed as an investment recommendation. Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. Additionally, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.

From time to time your free Options Profits Daily newsletter subscription is supplemented by paid sponsorships, like the one above. Please read all disclaimers. Rest assured that your information was not shared with this sponsor. Please note that Options Profits Daily has not independently reviewed the validity of the claims or statements contained within this sponsorship, and we are not responsible for any errors or omissions.

Never invest in a security or idea featured on our site or in our emails unless you can afford to lose your entire investment. We are not registered investment advisors or brokers/dealers and we do not purport to be. We make no representations, warranties or guarantees as to the accuracy or completeness of the content featured on our site or in our emails. Furthermore, the article authors and contributors featured on this site may own securities mentioned in their articles and not disclose this information. Options Profits Daily does not endorse any investing or trading products or newsletters advertised in this email or on our web site. Please be sure to read our Terms & Conditions, Disclaimer and Privacy Policy.

Go here to get more information from http://www.OptionsProfitsDaily.com